Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial
중증 COVID-19 환자의 회복기 혈장 수혈 요법- 안전성, 효능 및 용량 반응 연구: 2상 무작위 대조 시험 연구 프로토콜의 구조화된 요약
Letter
[키워드] (neutrophil
24 hour
24 hours
allergic
allergic reaction
Antibody titre
Arm
ARMS
automated
blinded
Blinding
body temperature
BSMMU
Care
checked
Clinical improvement
collaboration
collected
comparator
computer
Controlled
Controlled trial
convalescent plasma
COVID-19
creatinine
criteria
CRP
CT scan
deaths
defined
diastolic
discharge
dissemination
Donor
donors
dose
dose response
effective
effective dose
Efficacy
Efficacy and safety
element
ELISA
end point
enrolled
Evidence
evidence of
excluded
expected
FiO2
generate
Health Organization
hospital
Hospital stay
ICU
identify
in-hospital mortality
inclusion criteria
initial
intervention arms
Laboratory
laboratory parameter
Laboratory parameters
Laboratory tests
lactating women
lung
lymphocyte
multi-arm
multicentre
neutralizing antibody
neutrophil
normality
number
objective
open
outcome
Oxford
oxygen
oxygen saturations
PaO2
paO2/fiO2
participant
Participants
Patient
PCR assay
performed
plasma
Plasma transfusion
positive
pregnant
Primary outcome
proportion
protocol
random number table
randomised
Randomized controlled trial
RCT
receive
recorded
recording
recruit
recruited
recruitment
reduction in
required
respiratory
respiratory distress
respiratory rate
respiratory symptoms
room air
RT-PCR
RT-PCR assay
Sample size
sample size calculation
SARS-CoV-2
secondary outcome
serum creatinine
Serum ferritin
Seven
Severe case
severe cases
severe COVID-19
severe COVID-19 patient
severe COVID-19 patients
Severe patient
severe patients
Severe respiratory distress
Sex
SGOT
SGPT
SpO2
sputum
standard care
status
Study protocol
Support
systolic
the patient
therapy
These data
titre
transfusion
Treatment
Trial
university
University of Oxford
ventilator
website
World Health Organization
X-ray
[DOI] 10.1186/s13063-020-04734-z PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04734-z PMC 바로가기 [Article Type] Letter